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ABSTRACT
Local treatment failure after globe-conserving therapy for
choroidal melanoma is a surgical complication with
significant morbidity to the vision and eye. Few reports
in the literature have addressed this complication
exclusively. A review of the published literature with
reference to local treatment failure in the management
of choroidal melanoma was performed to make known
the potential differences in failure rates between
treatment modalities and methods. A search of the
literature regarding local treatment failure was performed
to identify relevant studies using combinations of the
following keywords on PubMed: uveal melanoma,
choroidal melanoma, local recurrence, local failure,
endoresection, gamma knife, radiotherapy, helium,
iodine, proton, palladium, ruthenium, trans-scleral
resection, transpupillary thermotherapy. Further studies
were found by searching the text and references of
previously identified studies for articles reporting local
treatment failure rates in choroidal melanoma. Among
the 49 studies identified, the local treatment failure rate
ranged from 0% to 55.6%, with follow-up ranging from
10 to 150 months. The two most widely used forms of
radiation therapy, iodine-125 and ruthenium-106
brachytherapy, were both associated with a local
recurrence rate of 9.6%. The weighted-average of
treatment failure in all radiation therapies was 6.15%
compared with 18.6% in surgical and 20.8% in laser
therapies. Rates of local treatment failure for
globe-conserving therapy of choroidal melanoma varied
widely between modalities and between centres using
similar modalities. Radiation therapy overall resulted in
lower local treatment failures compared with surgical or
transpupillary thermotherapy.
INTRODUCTION
Treatment of primary choroidal melanoma without
evidence of metastasis is either globe-conserving
therapy or enucleation. In a randomised clinical
trial of patients with primary choroidal melanoma
treated with globe-conserving iodine-125 brachy-
therapy vs enucleation, the Collaborative Ocular
Melanoma Study demonstrated no significant dif-
ference in mortality, during the period up to
12 years of post-treatment follow-up.1 Thus,
increasing emphasis has been placed on globe-
conserving therapy for choroidal melanoma.
Despite the fact that local treatment failure or
local recurrence is a recognised surgical complica-
tion of choroidal melanoma treatment, few reports
in the literature have addressed this complication
exclusively. However, local tumour control is a crit-
ical goal in the management of patients with chor-
oidal melanoma, because patients with local
treatment failure may have an increased risk of
metastasis and decreased survival.2 3 Moreover,
patients with local failure must undergo treatment
for their tumour recurrence, which generally
involves either further radiation or enucleation,
both of which are associated with increased mor-
bidity. Therefore, it is incumbent on those who
treat choroidal melanoma to minimise the risk of
local treatment failure or recurrence.
This review of the English language literature
regarding local treatment failure after globe-
conserving therapy presents the reported rates of
local failure following the various forms of radi-
ation, surgical ablation and transpupillary thermo-
therapy for choroidal melanoma. We also report
the median tumour size treated with each modality,
as larger tumour size has been shown to be asso-
ciated with a higher rate of local recurrence.4
Furthermore, we attempt to identify the risk factors
of local failure associated with the available treat-
ment modalities, and offer considerations to assist
clinicians and patients in treatment planning.
METHODS
A search of the literature regarding local treatment
failure was performed using the following key-
words on PubMed: uveal melanoma, choroidal
melanoma, local recurrence, local failure, endore-
section, gamma knife, radiotherapy, helium, iodine,
proton, palladium, ruthenium, trans-scleral resec-
tion, transpupillary thermotherapy. Additional
studies were found by searching the text and refer-
ences of previously identified studies of articles
reporting local treatment failure rates in choroidal
melanoma.
Inclusion criteria were: (1) English language
article, (2) the intervention had to be primary and
consist of one of the following: photon-based
external beam radiation, charged particle (proton,
helium ion) beam radiation, brachytherapy plaque
treatment (any isotope), surgical resection (any
method), or transpupillary thermotherapy, (3)
minimum reported mean follow-up of 0.5 years,
(4) minimum of 10 patients, (5) clear description
of follow-up methods.
Exclusion criteria were: (1) the criteria used for
diagnosing local treatment failure or recurrence
was not reported, (2) rates of local control were
reported by enucleation rate rather than an increase
in tumour growth, (3) patients who had previously
failed treatment for choroidal melanoma were
included, (4) publications including patient cohorts
that were subsequently included in reports of local
treatment failure with larger cohorts or longer
follow-up time, (5) the authors did not report
median or mean tumour largest basal diameter
(LBD) and/or height.
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We extracted the following information from each article that
met inclusion criteria: number of patients included, local treat-
ment failure rate, median or mean tumour LBD and height, and
length of follow-up (mean, median, or Kaplan–Meier estimate).
If the patient population was restricted (eg, only patients with
juxtapapillary tumours were included), this was noted.
When more than one local treatment failure rate was reported
in a given study, based on different lengths of follow-up, we
presented the rate of local failure for the follow-up time closest
to 60 months, to facilitate comparison among studies. The
60-month follow-up time was chosen because it was the length
most often used for Kaplan–Meier estimates, and also because it
was the length of time reported by the Collaborative Ocular
Melanoma Study.4
To facilitate comparison of different treatment modalities,
studies were grouped by treatment modality. Groups included
studies that used radiation, surgery and laser. Studies reporting
on radiation treatment were then further subgrouped based on
whether brachytherapy, photon-based external beam therapy, or
charged particle therapy was used. For each group and sub-
group, a weighted average of failure rate was calculated based
on the number of patients included in the respective studies.
RESULTS
Articles numbering 136 were identified with the search criteria.
After applying inclusion and exclusion criteria, 49 articles
remained for analysis. Rates of local treatment failure ranged
from 0% to 55.6%, and length of follow-up ranged from 10
months to 150 months. Study sizes ranged from 11 to 2435
patients, and the total number of patients included in the 49
articles was 12 524. The characteristics of the studies, including
first author, treatment centre, local treatment failure or recur-
rence rate, tumour LBD, tumour height, follow-up time, and
number of patients are summarised in table 1. Studies were
grouped by treatment modality, and the average local treatment
failure or recurrence rate for each treatment modality, weighted
by number of patients, was reported.
In table 2, radiation, surgical and laser modalities are com-
pared using the weighted mean rate of local treatment failure or
recurrence in the reports for each respective modality. Among
the treatment modalities using radiation, the mean local failure
rate ranged from 4.0% to 9.6%. Among surgical modalities, the
weighted mean local treatment failure or recurrence rate ranged
from 4.6% to 21.3%. Transpupillary thermotherapy was the
only laser modality used, and the weighted mean local treatment
failure rate for this modality was 20.80%. The weighted average
of local treatment failure or recurrence rates for radiation and
surgical modalities were 6.15% and 18.6%, respectively. The
tumours treated by surgical modalities were largest, with a
weighted mean tumour LBD and height of 12.96 mm and
7.98 mm, respectively. Tumours treated by radiation were
smaller, with a weighted mean tumour LBD and height of 12.90
mm and 5.21 mm, respectively. The smallest tumours were
treated by transpupillary thermotherapy, with a weighted mean
tumour LBD of 7.0 mm and height of 2.50 mm.
In table 3, the weighted mean local treatment failure rates of
various radiation modalities are compared. Among brachyther-
apy modalities, the weighted mean rate of local treatment
failure ranged from 4.0% to 9.6%. Among modalities using
photon-based external beam radiation therapy, the weighted
mean local failure rate ranged from 6.2% to 9.5%. Charged par-
ticle radiation treatment modalities had a mean local failure rate
ranging from 4.2% to 4.6%. The weighted average of local
treatment failure rates for brachytherapy, photon-based external
beam radiation therapy, and charged particle radiation therapy
were 9.5%, 7.9% and 4.2%, respectively. The two most com-
monly used forms of brachytherapy, iodine-125 and
ruthenium-106, were both associated with a weighted mean
local failure rate of 9.6%. The size of tumours treated among
the various radiation modalities were comparable. The weighted
mean tumour LBDs for brachytherapy, photon-based external
beam radiation therapy, and charged particle radiation therapy
modalities were 11.00 mm, 11.40 mm and 13.93 mm, respect-
ively. The weighted mean tumour heights among these modal-
ities were 4.48 mm, 6.15 mm and 5.54 mm, respectively.
DISCUSSION
The most striking finding of our review was that there was a
wide range of local treatment failures across centres. Overall,
radiation therapy was superior to surgical and laser therapies for
achieving local tumour control, with weighted mean local treat-
ment failure rates averaging 6.15% for radiation modalities,
18.6% for surgical modalities, and 20.8% for laser modalities.
Weighted mean tumour size was largest among surgical modal-
ities, followed by radiation modalities. The smallest tumours
were treated by laser with transpupillary thermotherapy. The
rate of local failure was lowest in eyes undergoing iodine-125
brachytherapy with intraoperative ultrasound localisation. The
rate of local failure was the highest in eyes undergoing trans-
scleral resection.
We recognise that the studies are heterogeneous because of
differences in follow-up time, patient population, surgical tech-
nique and threshold for defining local treatment failure or local
recurrence. Nonetheless, we consider the weighted mean local
failure rates determined to be an approximation of the true rate
for each treatment modality.
Radiation modalities
Radiation treatment modalities had the lowest rate of treatment
failures identified. Among radiation modalities, brachytherapy
and photon-based external beam radiation therapy had similar
rates of local treatment failure at 9.5% and 7.9%, respectively.
Charged particle radiation therapy, however, had a lower
weighted average rate of local failure at 4.2%. Local control in
radiation-treated choroidal melanomas is related to radiation
dose, dose rate, tumour location and length of follow-up.
Additionally, early failures are likely due to a ‘geographic miss’
of the tumour—that is, the entire tumour may not have been in
the radiation-targeted zone.5 Differences in any of these vari-
ables may account for the variability in local control rates
observed among different types of radiation therapy and also
among different centres using the same radiation modality (eg,
iodine-125 brachytherapy).
Brachytherapy
Brachytherapy failure rates were comparable among the various
isotopes used. However, local failure rates seemed to be affected
by whether or not ultrasound confirmation of brachytherapy
plaque placement was performed. Among the various isotopes
used for brachytherapy, iodine-125 and ruthenium-106 were the
most common.
Iodine-125 is a powerful, short-range gamma emitting radiation
source with excellent tissue penetration.6 Iodine-125 brachyther-
apy has local treatment failure rates ranging from 0% to 18%,
with a weighted average of 9.6%. Notably, the widely quoted mul-
ticenter Collaborative Ocular Melanoma Study reported a 5-year
local treatment failure rate of 10.3%,4 while several smaller studies
reported lower failure rates. Among the reports, two studies with
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Table 1 Local treatment failure rates, tumour dimensions, months of follow-up, and number of patients reported in the studies that met
inclusion criteria, by treatment modality
First author
Treatment
modality Treatment centre
Local
failure
rate (%)
Tumour
LBD (mm)
Tumour
height
(mm)
Months of follow
up
No.
pts. Notes
Radiation
Brachytherapy
Jampol (COMS
group)4
Iodine-125 Multicentre 10.3 11.5 4.2 60 650
Correa27 Iodine-125 Catalan Institute of
Oncology, Barcelona
11.8 12.2 5.9 60 120
Tabandeh8 Iodine-125 Bascom Palmer 1.7 9.6 4.2 37 117 Used intraoperative ultrasound
Sia28 Iodine-125 Royal Perth Hospital,
Australia
14.2 9.5 5.5 39.5 49
Quivey29 Iodine-125 UC San Francisco 18 10.9 5.5 60 239
Jensen30 Iodine-125 Mayo Clinic 8 11.2 4 74 156
Karlovits31 Iodine-125 Allegheny GH, Pittsburgh 0 13.5 7.8 60 35
Sobrin32 Iodine-125 Bascom Palmer 2.2 9.2 2.9 62.4 45
Leonard33 Iodine-125 Tufts University 27 12.3 6.3 100 37
Wilson14 Iodine-125 St Bartholemew’s
Hospital, Moorfields Eye
Hospital, London
4.2 10.2 5.9 47.3 190
Puusaari16 Iodine-125 Helsinki University 7 16.1 10.7 60 54
Sagoo34 Iodine-125 Wills Eye 14 10 3.5 60 242 Juxtapapillary choroidal
melanomas, 95% treated with
iodine-125, other 5% treated
with ruthenium-106, cobalt-60
McCannel7 Iodine-125 UCLA 0 10.8 4.8 32.4 170 Used intraoperative ultrasound
Weighted average
(n=13)
Iodine-125 9.6% 11.1 4.8 Total no. pts=2014
Rouberol35 Ruthenium-106 Hospital de la Croix
Rousse, Lyon, France
21.7 9 5 60 213
Novak-Andrejcic36 Ruthenium-106 University Eye Clinic,
Ljubljana, Slovenia
15.4 10.63 4.79 90.8 65
Verschueren12 Ruthenium-106 Leiden University 4 10.9 4.2 60 425 86.1% of patients also
received adjuvant TTT
Damato11 Ruthenium-106 Royal Liverpool University
Hospital
2.1 10.6 3.2 60 458 9.0% of patients received
adjuvant TTT
Wilson14 Ruthenium-106 St Bartholemew’s
Hospital, Moorfields Eye
Hospital, London
10.7 9.7 4.2 45.3 140
Papageorgiou37 Ruthenium-106 St Bartholemew’s
Hospital, London
14 9.5 3.7 60 189
Frenkel38 Ruthenium-106 Hadassah-Hebrew
University
14 13.1 4.7 66.6 413
Weighted average
(n=7)
Ruthenium-106 9.6% 10.9 4.1 Total no. pts=1653
Finger39 Palladium-103 New York Eye Cancer
Centre
4.0 10.3 3.9 55 100
Weighted average
(n=1)
Palladium-103 4.0% 10.3 3.9 Total no. pts=100
Leonard33 Cesium-131 Tufts University 9 12.6 5.4 20 11
Weighted average
(n=1)
Cesium-131 9% 12.6 5.4 Total no. pts=11
Photon-based external beam radiation therapy
Modorati40 Gamma knife
radiosurgery
San Raffaele Scientific
Institute, Milan
9 N/A 6.1 31.3 75
Zehetmayer41 Gamma knife
radiosurgery
University of Vienna 2 14.2 7.8 28.3 62
Sarici42 Gamma knife
radiosurgery
Istanbul University
Cerrahpasa Medical
School
10 10.3 8.7 40 50
Simonova43 Gamma knife
radiosurgery
Na Homolce Hospital,
Prague
16 N/A 8.5 32 75
Weighted average
(n=4)
Gamma knife
radiosurgery
9.5% N/A 7.7 Total no. pts=262
Continued
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Table 1 Continued
First author
Treatment
modality Treatment centre
Local
failure
rate (%)
Tumour
LBD (mm)
Tumour
height
(mm)
Months of follow
up
No.
pts. Notes
Dunavoelgyi44 Fractionated
radiotherapy
(stereotactic)
Medical University of
Vienna
4.1 11.2 4.8 60 212
Al-Wassia45 Fractionated
radiotherapy
(stereotactic)
McGill University Health
Centre
15 12 4 60 50
Weighted average
(n=2)
Fractionated
radiotherapy
6.2% 11.4 4.6 Total no. pts=262
Charged particle radiation therapy
Gragoudas46 Proton beam Massachusetts Eye and
Ear Infirmary
3.2 13 5.3 60 1922
Dendale47 Proton beam Curie Institute 4 13 4.8 60 1406
Mosci48 Proton beam Universita di Genova,
Centre A. Lacassagne
Cyclotron Biomedical—
Nice
8.4 14.2 6.2 46.8 368
Damato49 Proton beam Royal Liverpool University,
Clatterbridge Centre for
Oncology
3.5 10.1 3 60 349
Egger50 Proton beam Paul Scherrer Institute,
Switzerland
4.2 16.14 6.15 60 2435
Wilson14 Proton beam St Bartholemew’s
Hospital, Moorfields Eye
Hospital, London
5.2 11.7 6.6 43 267
Fuss51 Proton beam Loma Linda University 9.5 10 6 60 78
Weighted average
(n=7)
Proton beam 4.2% 14.0 5.5 Total no. pts=6825
Char52 Helium ion UC San Francisco 4.6 11.9 6.7 150 218
Weighted average
(n=1)
Helium ion 4.6% 11.9 6.7 Total no. pts=218
Surgery
Garcia-Arumi53 Endoresection Hospital Vall d’Hebron,
Barcelona
5.8 9.9 10.1 70.6 34
Kertes54 Endoresection Louisiana State University 3.1 8 5.3 40.1 32
Karkhaneh55 Endoresection Farabi Eye Hospital,
Tehran
5 11.67 8.51 89.6 20
Weighted average
(n=3)
Endoresection 4.6% 9.6 7.9 Total no. pts=86
Bechrakis56 Trans-scleral
resection
Innsbruck Medical
University, Austria
24 14.5 9.4 60 141
Damato57 Trans-scleral
resection
Royal Liverpool University 20 13.2 7.4 36 310
Weighted average
(n=2)
Trans-scleral
resection
21.3% 13.6 8.0 Total no. pts=451
Laser
Aaberg58 Transpupillary
thermotherapy
Emory University,
Michigan State University
23 8.5 2.3 60 135
Shields19 Transpupillary
thermotherapy
Wills Eye 22 6.5 2.7 36 256
Stoffelns59 Transpupillary
thermotherapy
Johannes Gutenberg
University, Germany
0 8.2 3 10 20
Godfrey60 Transpupillary
thermotherapy
Emory University 6.7 6.78 1.79 16 14
Harbour61 Transpupillary
thermotherapy
Washington University in
St Louis
24 7.3 2.6 21 32
Parrozzani62 Transpupillary
thermotherapy
University of Padova, Italy 11.6 6 2 48.7 77
Spire63 Transpupillary
thermotherapy
Hospital de la Croix
Rousse, Lyon, France
55.6 7.24 3.5 24.7 18
Weighted average
(n=7)
Transpupillary
thermotherapy
20.8% 7.0 2.5 Total no. pts=552
COMS, Collaborative Ocular Melanoma Study; LBD, largest basal diameter; N/A, not available; no., number; pts, patients; TTT, transpupillary thermotherapy; UC, University of California;
UCLA, University of California, Los Angeles; WA, weighted average.
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among the lowest treatment failure rates of 0% and 1.7% used
routine intraoperative ultrasound for plaque localisation during
brachytherapy.7 8 These data suggest that intraoperative ultrasound
plaque localisation during brachytherapy may reduce the risk of
local treatment failure. One can speculate that the optimised
plaque placement reduces geographic misses, thereby improving
local treatment success rates.
The weighted mean tumour LBD and height among studies
using iodine-125 brachytherapy were 11.1 mm and 4.8 mm,
respectively. In the Collaborative Ocular Melanoma Study,
tumours eligible for iodine-125 brachytherapy were less than
16.0 mm in LBD and 10.0 mm in height.9 The maximum
tumour height was 8.0 mm when the tumour was near the disc.
Many studies use these parameters to determine eligibility
for globe-sparing therapy. At the Jules Stein Eye Institute,
we use the following maximal dimensions for iodine-125
brachytherapy: apical height of 10 mm, and LBD of 16–17 mm,
with absolute necessity for ultrasound confirmation of borders.
Ruthenium-106 emits β-particles that only travel a limited
distance (4–5 mm)10; therefore, ruthenium-106 is most appropri-
ate for brachytherapy of tumours less than 5.4 mm in height.5 11
The weighted mean local failure rate among studies using
ruthenium-106 brachytherapy was 9.6%, identical to the rate cal-
culated for iodine-125. Local recurrence may be reduced when
adjuvant transpupillary thermotherapy is used in combination
with ruthenium-106 brachytherapy. The two studies that used
ruthenium-106 plaques and reported the lowest local failure rates
both used adjuvant transpupillary thermotherapy.11 12
Photon-based external beam radiation therapy
The rate of local treatment failure with photon-based external
beam radiation therapy (gamma knife radiosurgery or
Table 2 Comparison of radiation, surgical and laser treatment modalities
Modality
No. of studies
included
Weighted mean rate of local
failure (%)
Weighted mean tumour
LBD (mm)
Weighted mean tumour
height (mm)
No. of pts.
included
Radiation (n=11435)
Iodine-125 brachytherapy 13 9.60 11.10 4.80 2104
Ruthenium-106 brachytherapy 7 9.60 10.90 4.10 1653
Palladium-103 brachytherapy 1 4.00 10.30 3.90 100
Cesium-131 brachytherapy 1 9.00 12.60 5.40 11
Gamma knife radiosurgery 4 9.50 N/A 7.70 262
Fractionated radiotherapy 2 6.20 11.40 4.60 262
Proton beam radiation therapy 7 4.20 14.00 5.50 6825
Helium ion radiation therapy 1 4.60 11.90 6.70 218
Weighted average 6.15 12.90 5.21
Surgical (n=537)
Endoresection 3 4.60 9.60 7.90 86
Trans-scleral resection 2 21.3 13.60 8.00 451
Weighted average 18.6 12.96 7.98
Laser (n=552)
Transpupillary thermotherapy 7 20.80 7.00 2.50 552
Weighted average 20.80 7.00 2.50
LBD, largest basal diameter; No., number; Pts., patients.
Table 3 Comparison of radiation modalities
Modality
No. of studies
included
Weighted mean rate of local
failure (%)
Weighted mean tumour
LBD (mm)
Weighted mean tumour
height (mm)
No. of pts.
included
Brachytherapy (n=3868)
Iodine-125 brachytherapy 13 9.60 11.10 4.80 2104
Ruthenium-106 brachytherapy 7 9.60 10.90 4.10 1653
Palladium-103 brachytherapy 1 4.00 10.30 3.90 100
Cesium-131 brachytherapy 1 9 12.60 5.40 11
Weighted average 9.45 11.00 4.48
Photon-based external beam radiation therapy (n=524)
Gamma knife radiosurgery 4 9.50 N/A 7.70 262
Fractionated radiotherapy 2 6.20 11.40 4.60 262
Weighted average 7.85 11.40 6.15
Charged particle radiation therapy (n=7043)
Proton beam radiation therapy 7 4.20 14.00 5.50 6825
Helium ion radiation therapy 1 4.60 11.90 6.70 218
Weighted average 4.21 13.93 5.54
N/A, not available; No., number; pts., patients.
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fractionated radiotherapy) is similar to that of brachytherapy
(7.9% vs 9.5%). However, the risk of radiation-related ocular
side effects in the anterior segment is higher with external beam
radiotherapy, since the radiation beam travels through the anter-
ior segment in order to reach the tumour.5 This may result in
complications such as neovascular glaucoma, which ultimately
may require enucleation.
Charged particle radiation therapy
Proton beam and helium ion charged particle radiation treat-
ments are generated in a cyclotron, accelerated and delivered as
a particle beam. Their low scatter and focusability to a
maximum penetration (‘Bragg peak’) make them ideal for treat-
ing limited-sized lesions.13 However, all the tissue through
which the beam passes up to the Bragg peak, is exposed to the
nearly full radiation dose. This review found that the average
local treatment failure rate of charged particle radiation therapy
(proton beam or helium ion) was 4.2%. This rate is approxi-
mately one-half that of all forms of brachytherapy (9.5% vs
4.2%). One disadvantage of charged particle therapy is that,
similar to photon-based external beam radiation therapy, there
is collateral radiation damage in the tissues through which the
beam travels, usually the anterior segment structures.
Radiation-related side effects and complications of the anterior
ocular structures include chronic, severe dry eye, loss of lashes
and other eyelid abnormalities. There may also be a higher rate
of neovascular glaucoma.5 These complications are known to
occur at higher rates following charged particle treatment than
brachytherapy, and visual outcomes may be less favourable in
patients undergoing charged particle treatment.14 15 Moreover,
the use of charged particles is limited in availability, with the
majority of centres reporting outcomes located in Europe.
There is an increased interest in building new centres in North
America, however, and charged particle therapy may become
more widely available in the future.
Surgical modalities
Overall, surgical modalities had a higher rate of local treatment
failure compared with radiation modalities (18.6% vs 6.15%).
The weighted average local treatment failure rate using endore-
section was 4.6%. However, the weighted average local failure
rate for trans-scleral resection was 21%. The higher rate of local
treatment failure in patients treated with globe-conserving trans-
scleral resection may be related to the difficulty in achieving
clear surgical margins.16 17 The use of adjuvant ruthenium-106
plaques has been advocated for improving local failure rates in
patients treated with these surgical modalities, but this has not
significantly improved the local control rate.17 However, it
should be noted that the tumours selected for endoresection or
trans-scleral resection were larger than those treated by radi-
ation, with a weighted mean tumour height of 8.0 mm com-
pared with 5.21 mm. These tumours may have an inherently
faster growth rate with an associated increased risk for local
treatment failure.3
Laser modality: transpupillary thermotherapy
Of the treatment modalities reviewed, transpupillary thermo-
therapy had the largest reported variation of local treatment
failure from 0% to 55.6%, with a weighted average of 20.8%.
Some of the variability may be due to differences in tumour
characteristics, and the possibility of this treatment leaving some
tumour cells untreated.18 Shields et al showed that tumours
overhanging the optic disk and those that required more than
three transpupillary thermotherapy treatments had a greater risk
of local failure, and when such patients were excluded from the
study, the local failure rate decreased from 22% to 10%.19
Transpupillary thermotherapy is generally considered as a treat-
ment option for small choroidal melanomas, and the tumours
treated by this modality were the smallest in this series
(weighted mean tumour LBD and height were 7.0 mm and
2.5 mm, respectively). Due to the high local failure rate asso-
ciated with transpupillary thermotherapy, it may be of more
benefit as an adjunctive rather than a primary therapy. As previ-
ously noted, ruthenium-106 brachytherapy may be associated
with lower local recurrence rates when combined with transpu-
pillary thermotherapy.
Furthermore, continued support for the use of transpupillary
thermotherapy in ‘small choroidal melanomas’ may be based on
a perceived better efficacy for these lesions. However, based on
the knowledge and theories of transpupillary thermotherapy’s
efficacy in treating melanomas, any perceived superiority of this
treatment for ‘small melanomas’ may result from the consider-
able likelihood that these small lesions were actually benign
nevi. Observation continues to be an appropriate approach for
managing most benign choroidal lesions.
Morbidity associated with local treatment failure
The two main concerns regarding local treatment failure are (1)
increased morbidity to the eye and vision and (2) potential risk
of continued systemic tumour dissemination. There is no estab-
lished management for cases of local treatment failure. The
ultimate goal of controlling recurrent local growth may be
accomplished most conservatively by enucleation. If sparing the
globe is desired, repeat brachytherapy or transpupillary thermo-
therapy treatments may also be considered at the cost of
possible increased ocular morbidity. Additional radiation
increases the risk of vision-threatening ocular side effects, such
as optic neuropathy, radiation vasculopathy and neovascular
glaucoma, which may lead to eventual enucleation. The need
for retreatment also comes with a psychological toll for the
patient. In the Collaborative Ocular Melanoma Study Quality of
Life study report, patients who required enucleation after
brachytherapy had lower scores on all physical and mental
health measures than patients treated with either brachytherapy
or enucleation alone.20
Patients with local treatment failure also have a higher risk of
developing metastatic disease.3 21 However, it is not known
whether metastasis is influenced by the surgical complication of
local treatment failure or by the inherently aggressive nature of
the primary cancer. Given our current molecular understanding
of choroidal melanoma, metastatic risk may be more influenced
by the molecular make-up of the tumour, rather than by prolif-
erating cancer cells left in the eye after treatment. Certain cyto-
genetic abnormalities, most notably monosomy 3, have been
consistently associated with metastatic spread and death in chor-
oidal melanoma. Monosomy 3 is the most robust predictor of
metastatic death that has been identified to date.22 23 Although
it has not been proven, adequate local tumour control may
decrease metastatic risk by preventing tumour growth that
would ultimately lead to unfavourable cytogenetic abnormalities
more conducive to metastasis.24
Reducing local treatment failure
Overall, it is clear that radiation-based treatments are superior at
achieving local tumour control than non-radiation techniques.
The purpose of this review is not necessarily to convince the
reader of a specific treatment modality that is superior, but
to make known that significant and perhaps unacceptable
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variability exists between treatments. Although local treatment
failure may be determined by multiple tumour-related factors, it
is also very likely that local recurrence rates are affected by treat-
ment and quality-related factors, such as the surgeon’s ability
and experience.
There are also treatment-related factors that have been
described, or can be surmised. Gunduz et al found that the two
factors predictive of local treatment failure or recurrence in
macular choroidal melanomas treated by plaque radiotherapy
were distance to optic disk and presence of retinal invasion.21
The more posterior, or close to the optic disk, a tumour is
located, the more challenging it can be to place the brachyther-
apy plaque accurately to cover the tumours. Under such circum-
stances, ultrasound-guided placement techniques used
intraoperatively may improve the accuracy of plaque placement
and reduce the rate of local treatment failure.8 25 In support of
this notion is that the two reports of iodine-125 brachytherapy
with intraoperative ultrasound placement confirmation were
among the studies with the lowest published local treatment
failure rates of 0% and 1.7%.7 8
Strengths and limitations
Strengths of this study include the comprehensive nature of the
review and the inclusion of all available and applied treatment
modalities for globe-conserving management of choroidal mel-
anoma. The major limitation of this review is likely publication
bias favouring better outcomes, as poor outcomes are less likely
to be reported.26 Additionally, there is likely under-reporting of
surgical complications, such as local treatment failure, due to
the retrospective nature of the studies, and their inherent limita-
tion of variable follow-up. Therefore, the true rate of local treat-
ment failure is likely to be higher, perhaps much higher, than
the numbers reported herein. Moreover, this review is only able
to capture the local failure rates of centres that publish their out-
comes data. Tracking of outcomes data for quality improvement
purposes has not been widely adopted in Ophthalmology, and
these results, even when available, are not necessarily published.
Furthermore, the lack of cytopathologic diagnosis in nearly all
studies, makes it possible that some small lesions treated were
not choroidal melanomas, but instead misdiagnosed lesions,
such as benign choroidal nevi, metastatic lesions, circumscribed
choroidal haemangiomas, or even localized choroidal haemor-
rhages. This would, again, contribute to an underestimation of
the true local failure rate in the treatment of choroidal melan-
oma. Finally, the generalisability of our review is limited by the
lack of uniformity across studies in many factors that contribute
to local treatment failure, including tumour location, surgical
technique, dosimetry considerations for radiation modalities,
threshold for defining local failure and follow-up time. The
average local failure rate calculated from these studies may not
apply to another group of patients that differs significantly in
any of these factors.
Summary
Local treatment failure in choroidal melanoma is a devastating
complication for the patient. Overall, radiation-based therapies
for primary choroidal melanoma had a lower rate of local
failure at 6.15% compared with surgical and laser modalities, at
18.6% and 20.8%%, respectively. Among the various radiation-
based treatment modalities, the lowest rates of local treatment
failure were 0% and 1.7% reported by centres that used intrao-
perative ultrasound-guided iodine-125 brachytherapy plaque
location confirmation. Charged particle radiation therapy
(proton beam and helium ion) was also associated with a low
rate of local failure of 4.2%. Because the surgical complication
of local treatment failure is associated with an increased risk of
metastatic disease, poor patient vision, ocular morbidity and
diminished psychological status, it is important to prioritise the
achievement of local tumour control from the outset by combin-
ing the most optimal surgical technique with a treatment modal-
ity demonstrated to have a high local tumour control rate.
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